FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.

Chunli YinXiaoyan LinYige WangXianqiang LiuYi XiaoJingchao LiuAntoine M SnijdersGuangwei WeiJian-Hua MaoPengju Zhang

Published in: Cellular oncology (Dordrecht) (2020)

Our results suggest a role of FAM83D in NSCLC development. In addition, our results indicate that NSCLC patients exhibiting FAM83D overexpression are likely to benefit from AKT and/or mTOR inhibitor treatment.

Keyphrases

cell proliferation
epithelial mesenchymal transition
signaling pathway
small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
advanced non small cell lung cancer
transforming growth factor
cell migration